$1-million price tag set for Glybera gene therapy

@article{Morrison20151millionPT,
  title={\$1-million price tag set for Glybera gene therapy},
  author={Chris Morrison},
  journal={Nature Biotechnology},
  year={2015},
  volume={33},
  pages={217-218}
}
  • C. Morrison
  • Published 6 March 2015
  • Medicine
  • Nature Biotechnology
an annuity model that spreads that payment over a number of years to lessen the costdensity burden on payers; and a pay-forperformance, risk-sharing model that tracks patient outcomes and rewards manufacturers for maintaining patients’ health over a period of time. Each of these schemes is likely to be used, depending on the specific attributes of any one therapy and specific negotiations between drug manufacturers and payers. Rapid progress in the clinic may speed up such decisions. Bluebird’s… 

How will the field of gene therapy survive its success?

  • W. Kaemmerer
  • Engineering
    Bioengineering & translational medicine
  • 2018
An overview of the current status of the field of gene therapy with respect to its translation into practice is provided, including technical hurdles that have been overcome in the past decades and hurdles that need to be the subject of continued research.

The Daunting Economics of Therapeutic Genome Editing.

For this principle to hold true in clinical contexts, therapeutic genome editing must avoid several pitfalls that could substantially limit access to its transformative potential, especially in the developing world.

Gene therapy of hemoglobinopathies: progress and future challenges.

The most recent clinical trials for β-thalassemia and SCD are showing promising outcomes: patients were able to discontinue transfusions or had reduced transfusion requirements, however, toxic myeloablation and the high cost of current ex vivo HSC gene therapy platforms represent a barrier to a widespread application of these approaches.

Biogen and UPenn join forces to commercialize gene therapies

The recent gene therapy alliance between Biogen and the University of Pennsylvania (UPenn) offers further confirmation that the industrialization of gene therapy, though by no means complete, is now under way in earnest.

State of play and clinical prospects of antibody gene transfer

Overall, substantial progress has been made in the clinical translation of antibody gene transfer, with Viral vector-mediated mAb expression making the most significant strides.

The Landscape of Cellular and Gene Therapy Products: Cost, Approvals, and Discontinuations.

In the study period, more autologous cell therapy products were approved than allogenic agents, and the cost of gene and cell therapy drugs is much higher in the EU and North America in comparison to Asia.


Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan


A summary of the regulatory structure under which GTPs fall in the United States, the European Union, and Japan is provided, and a comprehensive overview of the Regulatory guidance applicable to the developer of GTP is provided.
...

References

SHOWING 1-3 OF 3 REFERENCES

First gene therapy approved

  • N. Moran
  • Medicine
    Nature Biotechnology
  • 2012
The European Commission granted marketing authorization for Glybera (alipogene tiparvovec) for the treatment of the ultra-rare inherited disorder, lipoprotein lipase (LPL) deficiency, on November 2, marking the beginning of a significant growth path for gene therapy.

Sovaldi makes blockbuster history, ignites drug pricing unrest

Payers could restrict uptake by allowing only the sickest patients onto Sovaldi, such as those with liver fibrosis or on the brink of a liver transplant, as well as be more aggressive with tiering and preferences.

The special case of gene therapy pricing

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.